Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28989734 | 1.00 | ALDH1A1 (0.49) | ALDH1A1THRBATML3MBTL1GAA | |
| SCHEMBL8426303 | 0.89 | GAA (0.54) | ALDH1A1THRBATML3MBTL1GAA | |
| SCHEMBL12914769 | 0.89 | PDE4B (0.42) | ALDH1A1THRBATML3MBTL1GAA | |
| SCHEMBL5629746 | 0.88 | EPHX2 (0.49) | ALDH1A1THRBATML3MBTL1GAA | |
| SCHEMBL22115760 | 0.88 | ALDH1A1 (0.43) | ALDH1A1THRBATML3MBTL1GAA | |
| SCHEMBL13198930 | 0.86 | KMT2A (0.41) | ALDH1A1POLBKDM4E | |
| SCHEMBL12914772 | 0.86 | KMT2A (0.41) | ALDH1A1POLBKDM4E | |
| SCHEMBL13644031 | 0.86 | GAA (0.56) | ALDH1A1THRBATML3MBTL1GAA | |
| SCHEMBL8324568 | 0.86 | POLB (0.50) | ALDH1A1THRBATML3MBTL1GAA | |
| SCHEMBL11088727 | 0.85 | ALDH1A1 (0.45) | ALDH1A1THRBATML3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024333-A | Oxime ether compound containing styryl and preparation method and application thereof | 贵州大学 | 2023-11-10 | — | — | CN | claimed |
| CN-116102565-A | Isolamine-containing spirochromone compound and preparation method and application thereof | 贵州大学 | 2023-05-12 | — | — | CN | claimed |
| CN-118164872-A | Eugenol compound containing Schiff base core skeleton, and preparation method and application thereof | 贵州大学 | 2024-06-11 | — | — | CN | disclosed |
| CN-118047763-A | Saturated nitrogen heterocyclic compound containing pyrimidine structure, and preparation method and application thereof | 贵州大学 | 2024-05-17 | — | — | CN | disclosed |
| CN-115991683-B | Cinnamic acid compound containing isopropanolamine structure, preparation method and application thereof | 贵州大学 | 2024-05-07 | — | — | CN | disclosed |
| CN-114751885-B | Coumarin compound containing isopropanolamine structure and preparation method and application thereof | 贵州大学 | 2023-08-08 | — | — | CN | disclosed |
| CN-115260046-B | Rosin acid ester compound and preparation method and application thereof | 贵州大学 | 2023-06-27 | — | — | CN | disclosed |
| CN-116102565-A | Isolamine-containing spirochromone compound and preparation method and application thereof | 贵州大学 | 2023-05-12 | — | — | CN | disclosed |
| CN-115991683-A | Cinnamic acid compound containing isopropanolamine structure, preparation method and application thereof | 贵州大学 | 2023-04-21 | — | — | CN | disclosed |
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| EP-2264026-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009110510-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | 萬有製薬株式会社 (JP) | 2009-09-11 | — | — | WO | disclosed |
| US-6964966-B2 | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments | WOCKHARDT LIMITED (IN) | 2005-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | ALDH1A1 1644/4885THRB 4781/4885ATM 2602/4885 |
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | NPY4R, NPY1R, NPY2R | ALDH1A1 4371/4885THRB 393/4885ATM 2471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.